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Background: Cranberry products have been implicated in several case reports to enhance the 
anticoagulant effect of warfarin. The mechanism could involve inhibition of the hepatic CYP2C9-
mediated metabolic clearance of warfarin by components in cranberry. Because dietary/natural 
substances vary substantially in bioactive ingredient composition, multiple cranberry products 
were evaluated in vitro before testing this hypothesis in vivo.
Methods: The inhibitory effects of five types of cranberry juices were compared with those of 
water on CYP2C9 activity (S-warfarin 7-hydroxylation) in human liver microsomes (HLM). 
The most potent juice was compared with water on S/R-warfarin pharmacokinetics in 16 healthy 
participants given a single dose of warfarin 10 mg.
Results: Only one juice inhibited S-warfarin 7-hydroxylation in HLM in a concentration-
dependent manner (P , 0.05), from 20% to .95% at 0.05% to 0.5% juice (v/v), respectively. 
However, this juice had no effect on the geometric mean AUC
0–∞ and terminal half-life of 
S/R-warfarin in human subjects.
Conclusions: A cranberry juice that inhibited warfarin metabolism in HLM had no effect on 
warfarin clearance in healthy participants. The lack of an in vitro–in vivo concordance likely 
reflects the fact that the site of warfarin metabolism (liver) is remote from the site of exposure 
to the inhibitory components in the cranberry juice (intestine).
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Introduction
Since 2003, accumulating case reports, one of which was fatal, have suggested a pos-
sible interaction between the oral anticoagulant warfarin and cranberry juice/products.1–3 
Most of the cases manifested as an increase in International Normalized Ratio (INR), 
which is a measure of anticoagulant response. Consequently, the labeling of warfarin 
has been revised to contain a warning to avoid cranberry juice/products.3 Warfarin is a 
racemic mixture, with the S-enantiomer having a greater pharmacologic potency than 
the R-enantiomer.4 S-warfarin is eliminated predominantly via metabolism in the liver 
to 7-hydroxywarfarin by cytochrome P450 (CYP) 2C9. Accordingly, any process that 
impairs hepatic CYP2C9 activity would be expected to increase systemic S-warfarin 
concentrations and potentially, the anticoagulant response. Optimal warfarin therapy 
is hindered by a narrow therapeutic window. This undesirable property, coupled with a 
wide interpatient variability in systemic S/R-warfarin concentrations and anticoagulant 
response, contributes to the high drug interaction liability of warfarin. Taken together, 
inhibition of hepatic CYP2C9 by components in cranberry juice/products has been pos-
tulated as a mechanism underlying this potential drug–dietary substance interaction.
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Very few controlled clinical studies have evaluated the 
effects of cranberry products on warfarin pharmacokinetics 
and pharmacodynamics. In healthy volunteers, cranberry 
juice5 and cranberry juice concentrate capsules6 had no effect 
on the pharmacokinetics of S /R-warfarin relative to water/
no treatment. Similarly, in warfarin-stabilized patients, cran-
berry juice had no effect on steady-state plasma S /R-warfarin 
concentrations relative to a placebo beverage.7 The reported 
effects of cranberry products on warfarin pharmacodynamics 
have been inconsistent. In warfarin-stabilized patients, one 
juice had no effect on INR,8 whereas another juice elicited an 
increase in INR, albeit on day 12.7 Cranberry juice concen-
trate capsules, relative to no treatment, elicited a 30% increase 
in the mean area under the INR versus time curve in healthy 
volunteers.6 A subsequent population pharmacokinetic-
pharmacodynamic analysis identified cranberry capsules as 
a significant covariate on S-warfarin EC
50
, ie, the capsules 
enhanced the potency of S-warfarin.6
Several potential factors contributing to the aforemen-
tioned inconsistencies include the dose and frequency of war-
farin and/or cranberry product administration, the statistical 
power of the study, and the composition/formulation of the 
cranberry product. Because dietary/natural substances vary 
substantially in the composition of bioactive ingredients,9 
one brand/formulation of a selected cranberry product cannot 
be considered representative of all others. Although some 
studies measured some components of the tested cranberry 
product,5,6 none conducted in vitro bioactivity testing of the 
cranberry product prior to initiation of the clinical study. 
Taken together, the aim of the current work was to utilize a 
systematic in vitro–in vivo approach to investigate a suite of 
cranberry juice products for potential inhibition of hepatic 
CYP2C9-mediated metabolism of S-warfarin.
Materials and methods
Materials and chemicals
Human liver microsomes (HLM, pooled from 50 donors 
of mixed gender) were purchased from Xenotech, LLC 
(Lenexa, KS). 7-Hydroxywarfarin was purchased from BD 
Biosciences (San Jose, CA). S-Warfarin, chlorowarfarin, sul-
faphenazole, high-pressure liquid chromatography (HPLC) 
grade water, methanol, ammonium acetate, and 1-propanol 
were purchased from Sigma-Aldrich (St Louis, MO).
Natural study materials and extraction/
fractionation procedures
The following bottled, nonfrozen cranberry juices were 
purchased from a local grocery store: Lakewood Organic 
Fresh Pressed Blend Cranberry (Lakewood, Miami, FL; 
Lot 147H); Ocean Spray Cranberry Juice Cocktail (Ocean 
Spray Cranberries, Inc., Lakeville-Middleboro, MA; Lot 
B0513060220); Market Pantry Juice Cocktail Cranberry 
(Target Corp., Minneapolis, MN; Lot 11F 13:11); 365 Brand 
100% Cranberry Juice (Whole Foods Market, Austin, TX; 
Lot 02/17/08); and R&W Knudsen Family Cranberry Juice 
Concentrate (Knudsen & Sons, Inc., Orville, OH). Accord-
ing to the manufacturer’s labeling, the Lakewood brand 
contained fresh pressed juice and puree from whole ripe 
certified organic apples, organic cranberries, and organic 
grapes; the Ocean Spray brand contained filtered water, 27% 
cranberry juice (from concentrate and cranberry juice), high 
fructose corn syrup, and ascorbic acid; the Market Pantry 
brand contained filtered water, high fructose corn syrup, 
27% cranberry juice (from concentrate), and ascorbic acid; 
the 365 brand contained filtered water, cranberry juice, and 
cranberry juice concentrate; and the Knudsen brand was a 
cranberry juice concentrate that contained no added sugars or 
other fruit juices. To avoid any potential bias, the identities 
of the juices were coded as vendors A, B, C, D, and E. Each 
juice was extracted and fractionated using established natural 
products chemistry techniques.10 The four fractions (hexane-, 
chloroform-, butanol-, and aqueous-soluble) generated from 
each juice were dried in vacuo and stored at -80° prior to 
the in vitro experiments.
Evaluation of cranberry juices  
and derived fractions as inhibitors  
of hepatic s-warfarin 7-hydroxylation
The inhibitory effects of each cranberry juice on hepatic 
S-warfarin 7-hydroxylation were evaluated using pooled 
HLM. S-warfarin and the CYP2C9 inhibitor, sulfaphenazole, 
were dissolved in methanol to yield working concentrations 
of 10 mM and 1 mM, respectively. Each juice was diluted in 
water to yield working concentrations of 5%, 20%, and 50% 
(v/v). NADPH was prepared fresh in potassium phosphate 
buffer (0.1 M, pH 7.4) to yield a working concentration of 
10 mM. Incubation mixtures, prepared in 96-well plates, con-
sisted of HLM (0.1 mg/mL microsomal protein), S-warfarin 
(4 µM), cranberry juice (0.05%, 0.20%, or 0.50%), and 
potassium phosphate buffer; control incubation mixtures 
contained water in place of juice. As a positive control for 
CYP2C9 inhibition, incubation mixtures contained sulfa-
phenazole (1 µM) in place of juice; control incubation mix-
tures contained 0.75% methanol in place of sulfaphenazole. 
The mixtures were equilibrated at 37°C on a solid heat block 
for five minutes before initiating the reactions with NADPH 
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(1 mM final concentration) to yield a final volume of 200 µL. 
After 30 minutes, reactions were quenched with 400 µL of 
cold methanol containing 3.33 nM chlorowarfarin as the 
internal standard. After centrifugation (1350 g for 10 minutes 
at 4°C), the supernatant was analyzed for 7-hydroxywarfarin 
by liquid chromatography-mass  spectrometry as described 
previously.11
Each of the four fractions generated from each cranberry 
juice (hexane-, chloroform-, butanol-, or aqueous-soluble) 
was dissolved in methanol to yield working concentrations 
of 1 and 5 mg/mL. Incubation mixtures were prepared in a 
similar manner as described for whole juices, except that the 
whole juice was replaced with juice fraction (10 or 50 µg/mL); 
control incubation mixtures contained 1% methanol in place 
of juice fraction.
Evaluvation of the most potent cYP2c9 
inhibitory cranberry juice on warfarin 
pharmacokinetics in healthy volunteers
A prospective, randomized, two-period crossover, open-label 
study was conducted at the University of North Carolina-
Chapel Hill General Clinical Research Center (GCRC). Both 
the Office of Human Research Ethics/Biomedical Institu-
tional Review Board and Clinical Research Advisory Com-
mittee reviewed and approved the study protocol. The study 
included a control (water) phase and treatment (cranberry 
juice) phase, which were separated by at least two weeks. 
Based on the in vitro data, cranberry juice from vendor E was 
selected for testing in the clinical study. Multiple bottles of 
juice E from the same lot were pooled to yield a uniform 
stock concentrate. “Double-strength” juice was prepared by 
diluting the concentrate with half the recommended volume 
of water. Common table sugar 5 g/oz (166 g/L) was added 
to improve palatability.
Prior to each volunteer’s participation, written informed 
consent and Health Insurance Portability and Accountability 
authorization were obtained. Subsequently, the volunteer 
underwent medical history review, physical examination, 
liver function tests, and complete blood count. Exclusion 
criteria included pregnancy or lactation, allergy to cranberry 
products, warfarin, or vitamin K, baseline INR . 1.2, history 
of significant medical conditions that the study physician 
believed would increase risk (eg, bleeding disorders), and 
concomitant modulators of CYP2C9 activity.
Healthy men and nonpregnant women (nine each) 
were enrolled. One man and one woman withdrew during 
the first phase due to a scheduling conflict and discomfort 
from venepuncture, respectively. Thus, 16 of the volunteers 
 completed the study. The participants, who ranged in age 
from 20–58 years, were self-identified as white (four men, 
six women), African American (three men, one woman), His-
panic (one man), or Asian (one woman). Some concomitant 
medications were allowed, and included oral contraceptives 
(n = 2), levothyroxine (n = 1), hydrochlorothiazide (n = 1), 
and multivitamins (n = 2), none of which are known to modify 
CYP2C9 activity. Moreover, since these medications are 
taken chronically, any possible effects on CYP2C9 activity 
were assumed to have reached steady state.
The participants were instructed to avoid all fruit juices 
for one week prior to and during the study and from alcohol 
and caffeinated beverages the evening prior to each study 
day. Participants were admitted to the GCRC the evening 
prior to each study phase. Vital signs (blood pressure, tem-
perature, pulse, respiration rate), INR, and oxygen satura-
tion were obtained at baseline and monitored periodically 
throughout the 24-hour inpatient period. After an overnight 
fast, each participant consumed three 240 mL glasses of 
water or double-strength cranberry juice, each separated by 
a 15-minute interval. Warfarin (Coumadin®; Bristol-Myers 
Squibb, Princeton, NJ) 10 mg was administered with the 
third glass.Vitamin K (Mephyton®; Merck, Whitehouse 
Station, NJ) 10 mg was administered concomitantly as a 
safety measure to counteract the warfarin anticoagulant 
effect. Prior to warfarin/vitamin K administration, 5 mL of 
blood was collected from an indwelling venous catheter and 
at 0.25, 0.50, 1, 1.50, 2, 3, 4, 6, 8, and 12 hours post-drug 
administration, after which the participant was discharged. 
The participant returned to the GCRC for outpatient blood 
collections at 24, 36, 48, 72, and 96 hours post-drug adminis-
tration. Blood was centrifuged within one hour of collection; 
plasma was saved and stored at -20°C pending analysis for 
S- and R-warfarin.
Analysis of human plasma  
for s- and r-warfarin
S- and R-warfarin and the internal standard, ethylwarfarin, 
were extracted from plasma by a one-step liquid/liquid 
extraction using t-butylmethylether under acidic condi-
tions. The analytes were separated and detected by HPLC/
UV using a 4.6 × 250 mm (R,R)-Whelk-O 1 Chiral column 
(Regis, Morton Grove, IL) and a 0.5% acetic acid/acetonitrile 
mobile phase. Calibration curves were obtained using a 
1/concentration2-weighted quadratic regression of response 
(normalized by the internal standard) versus concentration. 
Calibration curves were linear over the range 10–1000 ng/mL. 
Intra- and interday coefficients of variation were both less 
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than 12%. This method was validated according to Food and 
Drug Administration (FDA) guidelines.12
Pharmacokinetic analysis
S-warfarin and R-warfarin pharmacokinetics were evalu-
ated by noncompartmental methods using WinNonlin (v4.1; 
Pharsight Corp., Mountain View, CA). Predose below limit 
of quantification (BLQ) concentrations were set to zero; post-
dose BLQ concentrations were set to “missing” and excluded 
from the analysis. The terminal elimination rate constant (λ
z
) 
was estimated by linear regression of the terminal portion of 
the log-transformed concentration versus time curve using a 
minimum of three data points. The terminal half-life (t
1/2
) was 
calculated as ln(2)/λ
z
. The maximum observed concentration 
(C
max
) and time to reach C
max
 (t
max
) were obtained directly from 
the concentration-time profile. Area under the curve (AUC) 
from time zero to the last measured concentration (AUC
last
) 
was determined using the trapezoidal rule with linear up/
log down interpolation. The AUC from zero to infinite time 
(AUC
0–∞) was calculated as the sum of AUClast and the ratio 
of C
last
 to λ
z
. Apparent oral clearance (Cl/F) was calculated 
as the ratio of dose to AUC
0–∞. The S/R Cmax and AUC0–∞ 
ratios were calculated as S-warfarin C
max
/R-warfarin C
max
 and 
S-warfarin AUC
0–∞/R-warfarin AUC0–∞, respectively.
statistical analysis
All statistical analyses were carried out using SigmaStat 
(v3.5; Systat Software, Inc., San Jose, CA). The in vitro 
data are presented as means ± standard deviations (SDs) of 
triplicate determinations. Comparisons between the three 
concentrations of a given brand of cranberry juice were made 
using one-way ANOVA. Comparisons between the four 
generated fractions from a given cranberry juice brand were 
made using two-way ANOVA. Post hoc comparisons were 
made using Tukey’s test when an overall difference resulted 
(P , 0.05).
The sample size for the clinical study (n = 16) was 
calculated based on an 80% power to detect a 25% differ-
ence between cranberry juice E and water with respect to 
warfarin Cl/F. Medians and ranges are reported for t
max
. The 
Wilcoxon signed-rank test was used to detect a difference in 
t
max
. Geometric means and coefficients of variation (100 × SD 
of the natural log-transformed values) are presented for 
C
max
, AUC
0–∞, Cl/F, and terminal t1/2. Geometric means 
and 90% confidence intervals are presented for the ratio of 
cranberry juice to water with respect to C
max
, AUC
0–∞, Cl/F, 
and terminal t
1/2
. Paired two-tailed Student’s t-tests based on 
log-transformed data were used to detect differences between 
cranberry juice and water treatments. A P value , 0.05 was 
considered statistically significant.
Results
Effects of cranberry juices and derived 
fractions on hepatic s-warfarin 
7-hydroxylation in vitro
To identify a cranberry juice product to test in vivo, five 
cranberry juice products were evaluated as inhibitors of 
S-warfarin 7-hydroxylation activity in HLM. Relative to 
vehicle, only juice E inhibited activity in a concentration-
dependent manner, by 20% to .95% from 0.05% to 0.5% 
(v/v) juice, respectively (Figure 1). To characterize the juices 
further in terms of hepatic CYP2C9 inhibitory activity, 
each of the four fractions (hexane-, chloroform-, butanol-, 
aqueous-soluble) generated from a given juice was tested in 
HLM (Figure 2A–E). Consistent with the whole juices, the 
fractions from juice E, in aggregate, were the most potent, 
with all four fractions showing concentration-dependent inhi-
bition (Figure 2E). Of the juice E fractions, the chloroform-
soluble fraction was the most potent, inhibiting activity by 
30% and 75% at 10 and 50 µg/mL, respectively (Figure 2E). 
Only the chloroform-soluble fractions from juices A, B, C, 
and D showed concentration-dependent inhibition, from 
20% (juice A) to 46% (juice B) at 10 µg/mL and from 50% 
(juice A) to 90% (juice B) at 50 µg/mL (Figures 2A–D). 
The CYP2C9 inhibitor, sulfaphenazole, inhibited activity 
by $95% (data not shown).
Effects of cranberry juice E  
on the pharmacokinetics of s-  
and r-warfarin in healthy volunteers
As proof of concept, the effects of double-strength cran-
berry juice E were compared with those of water on the oral 
pharmacokinetics of S/R-warfarin in 16 healthy volunteers. 
Juice E was well tolerated by all subjects. Two subjects 
experienced mild nausea that resolved within a few hours. 
There were no vomiting episodes to affect the integrity of the 
pharmacokinetic data. No bleeding incidents were reported, 
and none of the subjects had elevated INR leading to study 
discontinuation.
None of the subjects were excluded from the pharmacoki-
netic analysis of S/R-warfarin. With S -warfarin, one subject 
during the water phase and one subject during the cranberry 
juice phase showed poor goodness-of-fit statistics for the ter-
minal elimination phase (adjusted R2 , 0.85). Accordingly, 
values for AUC
0–∞, Cl/F, and terminal t1/2 from these subjects 
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were excluded from the statistical analysis. The percentage 
of the AUC
0–∞ extrapolated to infinite time was ,25% for 
the majority of the subjects (n = 14) and did not exceed 30%. 
With R-warfarin, for one subject during the water phase, 
values for t
1/2,
 AUC
0–∞, Cl/F, and terminal t1/2 were excluded 
from the statistical analysis due to an adjusted R2 , 0.85. 
The percentage of the AUC
0–∞ extrapolated to infinite time 
was ,30% for the majority of subjects (n = 14) and was 
34% in one subject.
Relative to water, cranberry juice E slowed the systemic 
appearance of S-warfarin (Figure 3A), with the majority 
of subjects having measurable concentrations 15 minutes 
post-dose in the water phase versus 30 minutes post-dose 
in the cranberry juice phase. Juice E increased S-warfarin 
t
max
, by 0.3- to 7.0-fold, in all but one subject; median t
max
 
increased, significantly, by two hours (see Table 1). Juice E 
decreased S-warfarin C
max
, by as much as 50%, in all but one 
subject; the geometric mean C
max
 decreased significantly by 
27% (Table 1). The effects of juice E on S-warfarin AUC
0–∞, 
Cl/F, and terminal t
1/2
 were more varied; relative to water, the 
difference ranged from -34% to 40% (Figure 4A), -29% to 
52%, and -40% to 38% (Figure 4B), respectively. No sig-
nificant differences were detected between water and juice 
E for geometric mean Cl/F and terminal t
1/2
 (Table 1). The 
90% confidence interval for the cranberry juice-to-water ratio 
for C
max
 was outside, whereas that of AUC
0–∞ was within, the 
range 0.8–1.25 (Table 1).
In parallel with S-warfarin, cranberry juice E slowed 
the systemic appearance of R-warfarin relative to water 
(Figure 3B). Juice E increased R-warfarin t
max
, by 0.3- to 
7.0-fold, in all but two subjects; median t
max
 increased, signifi-
cantly, by five hours (Table 1). Juice E decreased R-warfarin 
C
max,
 by as much as 44%, in all but four subjects; the geomet-
ric mean C
max
 decreased significantly by 18% (Table 1). As 
observed with S-warfarin, the effects of juice E on R-warfarin 
AUC
0–∞, Cl/F, and terminal t1/2 were more varied; relative to 
water, the difference ranged from -13% to 48%, -32% to 
15%, and -39% to 28%, respectively. No significant differ-
ences were detected between water and juice E for geometric 
mean Cl/F and terminal t
1/2
, and the 90% confidence intervals 
for the cranberry juice-to-water ratios of C
max
 and of AUC
0–∞ 
followed the same trends as S-warfarin (Table 1).
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Figure 1 inhibitory effects of different brands of cranberry juice, coded A–E, on the 7-hydroxylation of s-warfarin in human liver microsomes. human liver microsomes 
(0.1 mg/mL) were incubated with s-warfarin (4 µM) and juice (0.05, 0.20, 0.50%, v/v) for 30 minutes. reactions were initiated by the addition of NADPh (1 mM). s-warfarin 
7-hydroxylation activity in the presence of vehicle control (water) was 5.7 ± 0.4 pmol/min/mg microsomal protein. Bars and error bars denote means and standard deviations, 
respectively, of triplicate incubations. *P , 0.05 versus 0.05% juice; #P , 0.05 versus 0.20% juice (one-way ANOVA, followed by Tukey’s test).
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Figure 2 inhibitory effects of the various fractions generated from the cranberry juice obtained from vendor A (A), B (B), c (C), D (D) and E (E) on the 7-hydroxylation 
of s-warfarin in human liver microsomes. human liver microsomes (0.1 mg/mL) were incubated with s-warfarin (4 µM) and juice fraction (10 or 50 µg/mL) for 30 minutes. 
reactions were initiated by the addition of NADPh (1 mM). s-warfarin 7-hydroxylation activity in the presence of vehicle control (1% methanol) was 2.3 ± 0.1 pmol/min/mg 
microsomal protein. Bars and error bars denote means and standard deviations, respectively, of triplicate incubations. *P , 0.05 versus 10 µg/mL; †P , 0.05 versus all other 
fractions at 10 µg/mL; ‡P , 0.05 versus all other fractions at 50 µg/mL (two-way ANOVA, followed by Tukey’s test).
Abbreviations: hex, hexane-soluble fraction; chlor, chloroform-soluble fraction; BuOh, butanol-soluble fraction; Aq, aqueous-soluble fraction.
S-warfarin C
max
 was higher than R-warfarin C
max
 in the 
majority of the subjects. Relative to water, cranberry juice E 
decreased the geometric mean S-to-R-warfarin C
max
 ratio 
significantly, by 11% (Table 1). In all but one subject, the 
AUC
0–∞ for S-warfarin was lower than that for R-warfarin. 
No significant differences were detected between water and 
juice E with respect to the geometric mean S-to-R-warfarin 
AUC
0–∞ ratio (see Table).
Discussion
Warfarin is prescribed worldwide for the treatment and preven-
tion of thromboembolic disorders. Although effective, warfarin 
therapy requires routine INR monitoring due to a narrow thera-
peutic range and large interpatient differences in anticoagulant 
response. Across a given patient population, the daily therapeu-
tic warfarin dose varies considerably.13 Both genetic and nonge-
netic factors contribute to these large  inter-patient differences. 
For example, genetic polymorphisms in the warfarin target 
gene, vitamin K epoxide reductase complex 1, account for up 
to 25% of these variations in dose requirements by affecting a 
patient’s sensitivity to warfarin.13,14 Genetic polymorphisms in 
the CYP2C9 gene account for another 15% of these variations 
by affecting a patient’s ability to eliminate warfarin. Moreover, 
because hepatic CYP2C9-mediated metabolism represents the 
major clearance pathway of the more pharmacologically active 
S-enantiomer, significant inhibition of CYP2C9 activity by 
nongenetic factors, such as concomitant medications, would be 
expected to enhance the systemic exposure of S-warfarin, and 
hence, the anticoagulant effect. Indeed, a number of clinically 
used CYP2C9 inhibitors, including fluconazole, amiodarone, 
and trimethoprim-sulfamethoxazole, have been associated with 
serious bleeding events in patients taking warfarin.15
In addition to concomitant medications, some dietary 
substances are known to influence warfarin response. For 
example, vitamin K-rich foods, such as dark green vegetables 
and some oils, are associated with warfarin resistance, and 
patients are counseled routinely regarding consistent intake 
of these foods.4 More recently, several case reports, including 
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Figure 3 Geometric mean concentration-time profile (0–96 hours) of S-warfarin 
(A) and r-warfarin (B) for 16 healthy volunteers given three × 240 mL glasses of 
water or sweetened double-strength cranberry juice (cBJ) E and a single oral dose of 
warfarin (10 mg). Insets depict the 0–12-hour time profiles. Symbols and error bars 
denote geometric means and upper limits of the 90% confidence interval, respectively.
one fatal event, have implicated a possible interaction 
between warfarin and cranberry juice/products. In most of the 
cases, larger than normal volumes/frequencies of cranberry 
product intake were associated with an increased INR. This 
drug-dietary substance interaction has been postulated to 
reflect inhibition of hepatic CYP2C9 activity by components 
in cranberry.1–3 Despite the lack of consistency among the 
scant controlled clinical trials regarding a warfarin-cranberry 
product interaction, the FDA in 2005 approved labeling 
changes cautioning patients about consuming cranberry 
juice/products while taking warfarin.3 Moreover, a medica-
tion guide developed by Bristol-Myers Squibb warns patients 
to avoid drinking cranberry juice or eating cranberry products 
while taking Coumadin.
Unlike drug products, of which the bioactive (and inactive) 
chemical entities are known and quantified, such information 
frequently is not available for dietary/natural substances. 
As a consequence, a major challenge with respect to the 
interpretation of drug–dietary/natural substance interactions 
is the substantial variation in the composition of bioactive 
components, which precludes between-study comparisons, as 
well as accurate predictions of the likelihood of a drug inter-
action. Accordingly, a systematic in vitro–in vivo approach 
involving multiple cranberry juice products was utilized to 
determine whether components in cranberry could inhibit 
the hepatic CYP2C9-mediated metabolism of S-warfarin. 
Of the five juices tested in vitro, only one (juice E) showed 
concentration-dependent inhibition of CYP2C9 activity 
(S-warfarin 7-hydroxylation) in HLM, with near ablation at 
just 0.5% juice (v/v). Likewise, all four fractions generated 
from juice E exhibited concentration-dependent inhibition, 
with the chloroform-soluble fraction showing the highest 
potency. Only the chloroform-soluble fraction from the 
remaining juices showed concentration-dependent inhibition. 
These observations suggested that the CYP2C9 inhibitors 
resided largely in this relatively lipophilic fraction. Although 
the fractions were not quantified in the juices, the negligible 
inhibitory effects of juices A–D, in contrast with juice E, 
could be due to variation in the amounts of chloroform-
soluble ingredients contained in these juices. Collectively, 
the differential effects of the various cranberry juice products 
on S-warfarin 7-hydroxylation further substantiate the prob-
ability that one dietary/natural substance is not representative 
of the broader marketplace. This contention is appreciated for 
consumer products, such as chocolates, coffees, and wines, in 
which profound differences in color, smell, taste, or texture 
reflect alterations in the growth, harvest, and/or processing 
of the materials. Such variability is overlooked frequently 
with dietary/natural products, for which similar variances can 
result in a different profile of bioactive constituents.
Based on the in vitro data, cranberry juice E was selected 
for evaluation on warfarin pharmacokinetics in healthy vol-
unteers. Relative to water, consumption of multiple glasses 
of double-strength juice had no significant impact on the total 
exposure of S-warfarin, as the 90% confidence interval of 
the AUC
0–∞ was contained within the reference 80%–125% 
bioequivalence range. However, the absorption of S-warfarin 
with juice E was slower compared with water. The median 
t
max
 increased by two hours, and geometric mean S-warfarin 
C 
max
 decreased by about 30%. Similar changes occurred 
with R-warfarin. The delay in warfarin absorption may have 
reflected changes in the physicochemical properties of the 
drug and/or delayed gastric emptying. This effect may be 
nonspecific, and possibly confounded by a decrease in gastric 
emptying rate elicited by the high sugar content in the double-
strength cranberry juice, because the same cranberry juice 
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Table 1 Pharmacokinetics of s- and r-warfarin in 16 healthy volunteers given a single oral dose of warfarin (10 mg) with water or sweetened 
double-strength cranberry juice from vendor E (3 × 240 mL glasses).
Measure Geometric mean (CV%) CBJ/water ratio P valuea
Water CBJ [90% CI]
s-warfarin
 tmax (h) [median (range)] 2.0 (0.5–4.0) 4.0 (3.0–8.0) 2.0
b ,0.001
 cmax (µM) 2.0 (29) 1.5 (24) 0.73 [0.66–0.80] ,0.001
 AUc0–∞ (µM * hour) 65 (30) 61 (29) 0.98 [0.89–1.07] 0.72
 cl/F (L/h) 0.25 (31) 0.27 (29) 1.02 [0.93–1.12] 0.72
 t1/2 (h) 32 (26) 32 (24) 1.02 [0.94–1.12] 0.66
r-warfarin
 tmax (h) [median (range)] 2.0 (0.5–12.0) 7.0 (3.0–12) 5.0
b ,0.005
 cmax (µM) 1.7 (22) 1.4 (14) 0.82 [0.75–0.89] ,0.005
 AUc0–∞ (µM * hour) 93 (21) 95 (14) 1.03 [0.90–1.09] 0.47
 cl/F (L/h) 0.18 (21) 0.17 (14) 0.97 [0.92–1.03] 0.47
 t1/2 (h) 42 (18) 42 (15) 0.79 [0.53–1.18] 0.91
s-to-r-warfarin ratios
 cmax,s-Warf/cmax,r-Warf 1.17 (21) 1.04 (23) 0.89 [0.83–0.95] ,0.05
 AUc0–∞,s-Warf/AUc0–∞,r-Warf 0.69 (30) 0.65 (32) 0.94 [0.89–0.99] 0.10
Notes: acomparisons between water and cBJ for tmax were made using the Wilcoxon signed-rank test; comparisons between water and cBJ for all other measures were 
made using the paired student’s t-test; bMedian difference between water and cBJ. 
Abbreviations: CBJ, cranberry juice; CI, confidence interval; tmax, time to reach maximum concentration (cmax); AUc0–∞, area under the curve from 0 to infinite time; Cl/F, 
apparent oral clearance; t1/2, terminal half-life.
product slowed the absorption of the CYP3A probe substrate, 
midazolam.10 However, unlike with midazolam, juice E had 
no effect on the geometric mean AUC
0–∞ of S- and R-warfarin, 
which is consistent with earlier studies following single-dose 
administration of warfarin and multiple exposures to a dif-
ferent brand of cranberry juice.5
Recently, using a similar systematic in vitro–in vivo 
approach involving multiple cranberry juice products, 
human intestinal microsomes, and midazolam 1’-hydroxy-
lation as an index of CYP3A activity, the juice showing 
the most potent inhibition of enteric CYP3A-mediated 
metabolism in vitro elicited a significant increase (∼ 30%) 
in midazolam systemic exposure in vivo; the lack of an 
effect on systemic t
1/2
 suggested that the juice inhibited 
intestinal, but not hepatic, CYP3A activity.10 In contrast, 
no change in total warfarin exposure was observed with the 
cranberry juice identified in the HLM system. The lack of in 
vitro-in vivo concordance with S-warfarin/HLM may reflect 
the fact that the site of warfarin metabolism (liver) is remote 
from the site of exposure to the inhibitory components in 
cranberry juice (intestine). The high oral bioavailability of 
warfarin (.90%) indicates that the drug undergoes negli-
gible first-pass metabolism in both the intestine and liver. 
The inhibitory CYP2C9 components in cranberry juice 
also may undergo biotransformation to inactive forms and/
or may be diluted in portal and hepatic arterial blood prior 
to entering the liver.
In summary, because dietary/natural products vary in com-
position of bioactive components, the warfarin–cranberry juice 
interaction was revisited using a systematic in vitro-in vivo 
approach involving multiple cranberry juice products. To 
the authors’ knowledge, such an approach had not been used 
previously. As anticipated, significant differences between 
juices were evident with respect to hepatic CYP2C9 inhi-
bition in vitro, confirming that one product should not be 
considered representative of all others; this view cannot 
be overstated with respect to any natural/herbal product.9,16 
A previous in vitro–in vivo study involving human intestinal 
microsomes and the probe CYP3A substrate, midazolam, 
successfully identified a cranberry juice product that inhibited 
enteric CYP3A activity in human volunteers.10 In contrast, 
the current work, which utilized a similar approach, failed to 
identify a juice capable of inhibiting hepatic CYP2C9 activity 
in human volunteers. The in vitro–in vivo discordance is likely 
due to the disparate sites of dietary substance delivery (intes-
tine) and probe substrate metabolic elimination (liver).
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Figure 4 Effects of three × 240 mL glasses of water and sweetened double-strength 
cranberry juice (cBJ) E on the AUc0–∞ (A) and terminal half-life (B) of s-warfarin 
in each of 16 healthy volunteers given a single oral dose of warfarin (10 mg). Open 
symbols connected by solid lines denote individual values. Filled symbols connected 
by dashed lines denote geometric mean values.
